FLT3-ITD和DNMT3A R882基因联合突变在急性髓系白血病中的研究进展  

Research progress of combined mutation of FLT3-ITD and DNMT3A R882 gene in acute myeloid leukemia

作　　者：杨槟荧 YANG Bin-ying(Medical College,Ningbo University in Zhejiang Province,Ningbo 315211,China)

机构地区：[1]宁波大学医学院,浙江宁波315211

出　　处：《中国当代医药》2018年第15期26-29,共4页China Modern Medicine

摘　　要：FLT3基因内部串联重复序列(FLT3-ITD)突变是急性髓系白血病(AML)中常见的突变类型,与AML的发生发展及不良预后密切相关。DNA甲基化转移酶3A(DNMT3A)突变在AML中发生频率较高,其中60%的突变发生在R882位点。DNMT3A R882突变在AML的发生发展过程中起重要作用,并提示预后不良。近几年研究发现FLT3-ITD合并DNMT3A R882基因突变的AML患者预后极差。本文结合目前研究成果,就FLT3-ITD和DNMT3A R882联合突变在AML中的发病机制、协同作用、临床特征、治疗以及预后进行综述。FLT3 mutation-internal tandem duplication（FLT3-ITD） mutation is a common type of mutation in acute myeloid leukemia（AML）,which is closely related to the occurrence,development and poor prognosis of AML.DNA methylation transferase 3 A（DNM-T3 A） mutation has a high frequency in AML.About 60% DNMT3 A mutations happened at codon R882.DNMT3 A R882 mutation plays an important role in the development of AML,and suggests poor prognosis.In recent years,studies have found that FLT3-ITD and DNMT3 A R882 mutations are both factors for poor prognosis of AML.Combined with the results of current research,this paper summarizes the pathogenesis,synergy,clinical characteri-stics,treatment and prognosis of combined mutation of FLT3-ITD and DNMT3 A R882 in AML.

关 键 词：FLT3基因内部串联重复序列 DNMT3A R882 急性髓系白血病 预后 造血干细胞移植 

分 类 号：R733.71[医药卫生—肿瘤]